When was Cogent Biosciences founded?

Cogent Biosciences was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is Cogent Biosciences located?

Cogent Biosciences is headquartered in Cambridge, United States.

Who is the current CEO of Cogent Biosciences?

Charles Wilson of Cogent Biosciences. They have also founded 1 company and are an angel investors in 1 startup.

How many employees does Cogent Biosciences have?

As of Apr 30, 2026, the latest employee count at Cogent Biosciences is 287.

Is Cogent Biosciences a funded company?

Cogent Biosciences is a funded company, having raised a total of $77M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 21, 2014.

When was the latest funding round of Cogent Biosciences?

Cogent Biosciences' latest funding was a $***** Post IPO round on Feb 14, 2024, with participation from 8 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $595M in funding in 2026 to date.

What is the annual revenue of Cogent Biosciences?

Annual revenue of Cogent Biosciences is $7.87M as on Dec 31, 2020.

Where does Cogent Biosciences rank among its competitors?

Cogent Biosciences ranks 425th amongst 3613 active competitors, of which 1242 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Biosciences, which secured $40M in May, 2026.

Who are the top competitors of Cogent Biosciences?

Cogent Biosciences' top competitors include Jazz Pharmaceuticals, BridgeBio and BeiGene. Among them, Senti Biosciences secured the most recent funding round in May, 2026.

Cogent Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Cogent Biosciences is a developer of precision therapy for treating diseases like cancer, rare diseases, autoimmune conditions & others. The company is developing solutions to treat genetically driven diseases & its lead therapeutic product PLX9486 is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. It is also developing PLX9486 to treat gastrointestinal stromal tumors (GIST) which is dependent on oncogenic KIT signaling.

Website: www.cogentbio.com/
Social
Email ID: *****@cogentbio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

Cambridge, United States

Stage

Public

Total Funding

$77M in 6 rounds

Latest Funding Round

Post IPO, Feb 14, 2024, $*****

Investors

Atlas Venture & 22 more

Ranked

425^th among 3613 active competitors

Annual Revenue

$7.87M as on Dec 31, 2020

Employee Count

287 as on Apr 30, 2026

Investment & Acquisitions

kiq.com

Similar Companies

Jazz Pharmaceuticals & 3462 more

Exit Details

Public

View Cogent Biosciences' full profile

Cogent Biosciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cogent Biosciences, Inc. CIN: 20201960227 , United States, Active	Nov 05, 2020	-	-	-
UNUM THERAPEUTICS INC. CIN: 1622229 , United States, Active		$7.87M (As on Dec 31, 2020)	-	-
Cogent Biosciences, Inc. CIN: 46-5308248 , United States, Active	Oct 02, 2014	-	164 (As on Dec 31, 2023)	-

Cogent Biosciences got listed on Mar 29, 2018.

Click here to take a look at Cogent Biosciences's IPO in detail

Cogent Biosciences has raised a total funding of $77M over 6 rounds. Its first funding round was on Oct 21, 2014. Its latest funding round was a Post IPO round on Feb 14, 2024 for $*****. 8 investors participated in its latest round. Cogent Biosciences has 23 institutional investors.

Here is the list of recent funding rounds of Cogent Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 14, 2024	9397566	Post IPO	1219162	3550758	7234477	9853508
Jul 06, 2020	6181876	Post IPO	2772945	5718038	4407210	3663976
Mar 20, 2020	9618267	Post IPO	7566811	3999014	2406404	Lincoln Park Capital

Access funding benchmarks and valuations. Sign up today!

View details of Cogent Biosciences's funding rounds and investors

The founders of Cogent Biosciences is Charles Wilson. Charles Wilson is the CEO of Cogent Biosciences.

Here are the details of Cogent Biosciences' key team members:

Charles Wilson: Founder & CEO of Cogent Biosciences. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of Cogent Biosciences's Founder profiles and Board Members

Cogent Biosciences' employee count trend

Cogent Biosciences has 287 employees as of Apr 26. Here is Cogent Biosciences's employee count trend over the years:

Employee count trend for Cogent Biosciences

Uncover Cogent Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cogent Biosciences include Jazz Pharmaceuticals, BridgeBio and BeiGene. Here is the list of Top 10 competitors of Cogent Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
5th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
6th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 27 others	77/100
7th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
9th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
10th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
425th	Cogent Biosciences 2014, Cambridge (United States), Public	Developer of precision therapy for genetically defined diseases	$77M	Lincoln Park Capital, Wellington & 21 others	56/100